AUPH - Aurinia Pharmaceuticals Stock Price, Chart, News and Analysis
AUPH news
Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH): What does the company do?
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Unlock full access
Every scanner, the BH Indicator, insider and options flow, sector and industry rankings, the themes, the trading journal and the daily briefings from the Senior Analyst.
See plans →Breakouts Happen publishes market analysis and screening tools. Every idea, opinion and forecast on this site — stated or implied — is provided for informational purposes only and is not a recommendation to invest, trade or speculate in any market. Any position taken in light of the material published here is taken at your own risk, financial or otherwise. Breakouts Happen is not a registered investment advisor, and nothing on this site is an offer or solicitation to buy or sell any security.
Market data is delayed and provided for reference only. Past performance does not indicate future results.